Synopsis:
On 1st September 2025, Anondita Medicare Ltd attracted notable attention on the NSE, with multiple bulk transactions highlighting strong institutional and investor interest. The activity reflects growing confidence in the company’s growth prospects and market potential.
The shares of this healthcare company that manufactures flavored male condoms, with its flagship product branded as “COBRA” are in focus after seeing institutional buying as bulk deals.
With market capitalization of Rs. 549 cr, the shares of Anondita Medicare Ltd are currently closed at Rs. 303.70 per share, locked at 5% upper circuit from its previous close of Rs. 289.25 per share.
Bulk Deals
On 1st September 2025, Anondita Medicare Ltd witnessed significant bulk purchase activity on the NSE, reflecting strong institutional interest. Notable transactions included Cinco Stock Vision LLP acquiring 1,00,000 shares at an average price of Rs. 275.50 per share, Devi Traders LLP purchased 1,05,000 shares at Rs. 275, and SageOne – Flagship Growth OE Fund bought 2,00,000 shares at Rs. 275.50. SageOne – Flagship Growth 2 Fund acquiring 1,01,000 shares at an average price of Rs. 271.85 per share.
Other key buyers included Laroia Mona with 1,60,000 shares at Rs. 280.70 and Ritu Bapna acquiring 2,55,000 shares at Rs. 278.98. Overall, the bulk deals indicate robust demand from various funds and investors, suggesting confidence in the company’s prospects.
Also Read: Steel stock jumps 6% after receiving ₹170 Cr order for power project
About the company
Anondita Medicare Ltd, established in 2024, is a prominent Indian manufacturer specializing in personal healthcare products. Operating from its state-of-the-art facility in Noida, Uttar Pradesh, the company boasts an annual production capacity of approximately 562 million condoms. Additionally, Anondita Medicare has expanded its product line to include female condoms and latex surgical gloves.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
